Coming Down the Pike: Bispecific mABs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Coming Down the Pike: Bispecific mABs


Pharmaceutical Technology


BiTE antibodies may be able to fight cancer cells such as this one.(PHOTO: GEOSTOCK/GETTY IMAGES)
Antibodies are highly specific molecules that can be tailored to recognize almost any stretch of peptide that nature can conjure: a feature that has been exploited for years now to produce therapeutic antibodies.

In the most common scenario, an antibody is created that homes in on a particular protein—generally one abnormally expressed to produce a disease condition—binds to it, and blocks its activity. The anti-breast cancer drug Herceptin functions this way, for example.

But within the past 10 years, scientists have been experimenting with antibodies that recognize two peptide sequences—often on two different cell types—at once. These so-called bispecific monoclonal antibodies (Bi-mAbs) are often engineered to recognize a sequence on cytotoxic, or "killer" T-cells as well as a sequence on tumor cells, the idea being that the Bi-mAb literally links together a killer cell with its tumor-cell target.

Writing in Drugs of the Future 2008, scientists at Micromet Inc. (Bethesda, MD) say that most of these drugs have not been "suitable for formal pharmaceutical development, generally due to issues of production and lack of potency." And speaking at the Biotechnology Industry's Organization CEO and Investors Conference this February, Micromet CEO Christian Itin revealed the company's next-generation Bi-mAbs, which they call BiTE antibodies.

BiTE antibodies combine only the variable domains of antibodies and therefore are approximately one-third the size of conventional antibodies. Scientists report that BiTE antibodies have been extremely successful at inducing the normal "killer" T-cell response in a highly specific manner against tumor cells, while skirting many of the usual side effects of mAb therapies. The company has its first such BiTE antibody in Phase I trials for non-Hodgkins lymphoma and has several more against various tumor types in its development pipeline.

References

1. P. A. Baeuerle et al., "BiTE: A New Class of Antibodies that Recruit T-Cells," Drugs of the Future 2008, 33 (2), (2008).

2. C. Renner et al.," Cure of Xenografted Human Tumors by Sispecific Monoclonal Antibodies and Human T Cells," Science 264, 833–835 (1994).

3. M. Brennan et al., "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments," Science 229, 81–83 (1985).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here